Most types of non-Hodgkin lymphoma (NHL) form from B cells, which can be indolent (slow-growing) or aggressive (fast-growing).

Diffuse large B-cell Lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 30% of malignant lymphomas. It represents a heterogenous group of lymphomas involving the lymph nodes or different extranodal sites, and is an aggressive but treatable cancer.

The median age at occurrence of DLBCL is 60 years and patients usually present with disseminated disease. The standard of care for DLBCL remained the CHOP regimen for decades, which achieved long term remission rates in around 45% of patients. Following the introduction of rituximab, a chimeric anti-CD20IgG1 monoclonal antibody, long-term remission has been observed in ~60% of patients. However, a significant number of patients are rituximab refractory at relapse.Newer therapies such as CAR-T cells, immunomodulators, antibody-drug conjugates, and BTK inhibitors have further improved outcomes for patients with relapsed disease, with further research ongoing to improve outcomes for these patients, and further improve upfront therapy.

View Lymphoma Overview Page

Aggressive & Diffuse Large B-Cell Lymphoma

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics.

The supporters have no influence over the production of the content.


If you are interested in becoming a supporter of The Lymphoma Channel, please contact us

Aggressive & Diffuse Large B-Cell Lymphoma

Most types of non-Hodgkin lymphoma (NHL) form from B cells, which can be indolent (slow-growing) or aggressive (fast-growing).

Diffuse large B-cell Lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 30% of malignant lymphomas. It represents a heterogenous group of lymphomas involving the lymph nodes or different extranodal sites, and is an aggressive but treatable cancer.

The median age at occurrence of DLBCL is 60 years and patients usually present with disseminated disease. The standard of care for DLBCL remained the CHOP regimen for decades, which achieved long term remission rates in around 45% of patients. Following the introduction of rituximab, a chimeric anti-CD20IgG1 monoclonal antibody, long-term remission has been observed in ~60% of patients. However, a significant number of patients are rituximab refractory at relapse.Newer therapies such as CAR-T cells, immunomodulators, antibody-drug conjugates, and BTK inhibitors have further improved outcomes for patients with relapsed disease, with further research ongoing to improve outcomes for these patients, and further improve upfront therapy.

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics.

The supporters have no influence over the production of the content.


If you are interested in becoming a supporter of The Lymphoma Channel, please contact us

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter